Asana BioSciences

Lawrenceville, United States Founded: 2014 • Age: 12 yrs
Clinical-stage biopharmaceuticals for oncology and related diseases are developed.
Annual revenue - Latest available
Total funding - 1 rounds
Employees 7 Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 8 Brand Intelligence

About Asana BioSciences

Asana BioSciences is a company based in Lawrenceville (United States) founded in 2014. The company has 7 employees as of December 31, 2022. Asana BioSciences operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.

  • Headquarter Lawrenceville, United States
  • Employees 7 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Asana Biosciences, Llc.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    7

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Asana BioSciences

Investors in Asana BioSciences

Asana BioSciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Tarsadia.

All
Venture Fund
Investor Description Founded Year Domain Location
Venture capital and private equity are directed toward multiple sectors.
Locked Locked Locked
Premium access

Investor details for Asana BioSciences

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Asana BioSciences

Investments
Premium access

Investment portfolio details for Asana BioSciences

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Asana BioSciences

Premium access

Detailed financials for Asana BioSciences

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Asana Biosciences Comparisons

Asana BioSciences Primary company
Description
Clinical-stage biopharmaceuticals for oncology and related d...
Location
Lawrenceville, United States
Founded Year
2014
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
7
As of 2022
Premium access

Peer comparison for Asana BioSciences

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Asana BioSciences

Asana BioSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
Locked Locked Locked
Small molecule therapeutics for cancer treatment are developed.
Locked Locked Locked
Cancer therapies are developed using selective pathway inhibitors.
Locked Locked Locked
MicroRNA-based therapeutics are developed for treating multiple diseases.
Locked Locked Locked
Therapeutics for cancer and rare diseases are developed.
Premium access

Detailed competitors of Asana BioSciences

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Asana Biosciences

Premium access

Complete news archive for Asana BioSciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Asana BioSciences

Asana BioSciences was founded in 2014.

Asana BioSciences is headquartered in Lawrenceville, United States.

As of Dec 31, 2022, the latest employee count at Asana BioSciences is 7.

Asana BioSciences is clinical stage biopharma with a focus on oncology. Other therapeutic areas include pain, dermatology and autoimmune diseases. Asanas lead candidates, ASN001 and ASN002 are in Phase III clinical development. ASN001, a novel and highly selective CYP17 inhibitor that does not require prednisone co-administration, targets metastatic castration-resistant prostate cancer. ASN002 is a novel oral inhibitor of spleen tyrosine kinase (SYK) and Janus kinase (JAK), which is currently in Phase III studies in patients with non-Hodgkins lymphoma and solid tumors. Evaluation of ASN002 in autoimmune disease indications is also being planned. Both these programs are approaching the end of dose-finding phase of the trials, and Asana expects to announce initial safety and efficacy results in early 2007. ASN003 is a selective RAFPI3K inhibitor whose IND was accepted by FDA in Oct 2016. ASN004 is an antibody drug conjugate (ADC) targeting 5T4-oncofetal antigen that selectively and efficiently delivers a cytotoxic agent into tumor cells, resulting in selective anti-proliferative activity and complete tumor regression in multiple tumor models including breast, lung and colon. ASN007 is a novel ERK inhibitor that shows activity against multiple KRAS mutant driven tumor models. These programs will enter clinical development in 2H 2017.,.

Asana BioSciences's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

Asana BioSciences has 1 investor. Key investors include Tarsadia.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available